Detalhe da pesquisa
1.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation
; 145(8): 575-585, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903039
2.
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.
Kidney Int
; 103(2): 403-410, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341885
3.
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 383(15): 1436-1446, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970396
4.
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Nephrol Dial Transplant
; 38(4): 894-903, 2023 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35700142
5.
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Nephrol Dial Transplant
; 38(9): 2041-2051, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651820
6.
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
Diabetes Obes Metab
; 25(7): 1932-1941, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945734
7.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
; 65(7): 1085-1097, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445820
8.
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Circulation
; 143(5): 438-448, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186054
9.
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.
Cardiovasc Diabetol
; 21(1): 12, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35057807
10.
Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline.
Ann Intern Med
; 174(9): 1270-1281, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152826
11.
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.
Kidney Int
; 99(3): 559-569, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637203
12.
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
Diabetes Obes Metab
; 23(9): 2058-2066, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34009708
13.
Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD.
Curr Cardiol Rep
; 23(9): 132, 2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34398316
14.
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.
Eur Heart J
; 41(2): 231-238, 2020 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30590564
15.
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake.
Eur Heart J
; 41(35): 3363-3373, 2020 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33011774
16.
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Kidney Int
; 98(4): 1044-1052, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32450154
17.
International consensus definitions of clinical trial outcomes for kidney failure: 2020.
Kidney Int
; 98(4): 849-859, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998816
18.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(9): 839-848, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854085
19.
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
Diabetes Obes Metab
; 22(11): 2077-2088, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618386
20.
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
Eur Heart J
; 40(25): 2032-2043, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30919899